TRVN:OTCMKTS
Trevena Inc
0,066 $
0,00%
(0,00) 1 d.
12. okt., 14:57:26 GMT-4 · USD
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: TRVN…
Tirgus kapitalizācija
57,01 tūkst.
Vid. apjoms
210,00
Apjoms
9,00
Augstākā 52 ned.
1,50 $
Zemākā 52 ned.
0,00 $
Beta
1,07
Apgrozībā esošās akcijas
864,00 tūkst.
Darbinieku skaits
23
Tirgus kapitalizācija
57,01 tūkst.
Vid. apjoms
210,00
Apjoms
9,00
Augstākā 52 ned.
1,50 $
Zemākā 52 ned.
0,00 $
Beta
1,07
Apgrozībā esošās akcijas
864,00 tūkst.
Darbinieku skaits
23
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
TradingView
·
pirms 40 minūtēm
Key facts: NASDAQ:ASTS delayed 2027; Piper Sandler Neutral; $1B note
Moomoo
·
pirms 36 minūtēm
Dow Jones Top Company Headlines at 3 AM ET: Tesla's New Roadster Takes Flight After Nearly a Decade of Delays | Schneider ...
Bloomberg
·
pirms 21 minūtes
European Shares Outperform S&P 500 Amid Defensive Tilt From AI
Investor's Business Daily
·
pirms 4 stundām
Futures Mixed; Anthropic Value, Tesla Roadster In Focus
Profils
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week.
Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
Par “Trevena Inc”
Ģenerāldirektors-
Darbinieki23
Dibināšanas datums2007
Galvenais birojsAtlanta, Džordžija, Amerikas Savienotās Valstis
Sektors-
Tīmekļa vietnetrevena.com